LONDON-The World Health Organization is working with the world's six largest medical journal publishers to bring the latest medical information to developing nations.
Medical journals tend to be expensive, with some of the more predominant journals asking $1500 for an annual subscription. Under United Nation's Secretary-General Kofi Annan's new Health InterNetwork program, the WHO and publishing companies have teamed to shorten the communication gap between the developed and developing worlds.
The program was created to strengthen public health services by giving public health workers the same access to timely information through an Internet portal.
The journals will be sent to countries and hospitals beginning January, 2002. Officials from both the WHO and the publishing companies will determine during the rest of 2001 who will receive the journals.
The publishing companies that will be donating their journals are: Blackwell, Elsevier Science, the Harcourt Worldwide STM Group, Wolters Kluwer International Health and Science, Springer Verlag, and John Wiley.
Information from www.washingtonpost.com
For more information about the WHO visit: www.who.org
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.